文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

预配制冲洗液Bactisure®在急性假体周围关节感染清创手术中的疗效:随机对照试验研究方案

Efficacy of the preformulated irrigation solution Bactisure® in acute periprosthetic joint infection debridement surgery: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2024-11-16

本研究为前瞻性单中心随机对照试验,纳入2022年12月至2024年12月接受标准DAIR手术的急性血源性假体周围关节感染患者,按1:1随机分为生理盐水对照组(n=25)和Bactisure®预配制冲洗液试验组(n=25),主要结局为1年感染治愈率,样本量基于再感染率从对照组45%降至试验组10%的预期计算,所有患者随访至少12个月。

要点

  • 前瞻性单中心随机对照试验比较Bactisure®与生理盐水在DAIR术中的感染治愈率。
  • 对照组(n=25)用生理盐水,试验组(n=25)用Bactisure®预配制冲洗液,1:1随机。
  • 主要结局为1年感染治愈率,所有患者随访至少12个月。

核心结论

  • 作者主要假设是,与生理盐水相比,Bactisure®在DAIR术后1年提供更好的感染治愈率。
  • 本研究是首个在真实临床实践(体内)中比较Bactisure®预配制冲洗液与生理盐水在急性膝和/或髋假体周围感染DAIR患者中有效性的研究。

研究设计与样本

  • 前瞻性单中心随机对照试验,纳入2022年12月至2024年12月接受标准DAIR手术的急性血源性假体周围关节感染患者。
  • 按1:1比例随机分为对照组(n=25)使用生理盐水冲洗液和试验组(n=25)使用Bactisure®预配制冲洗液。
  • 样本量基于再感染率从对照组45%降至试验组10%的预期计算,所有患者随访至少12个月。

关键数值与推荐

  • 主要结局为DAIR术后1年感染治愈率。
  • 样本量计算基于预期再感染率从对照组45%降至试验组10%。
  • Bactisure®预配制冲洗液含乙醇、乙酸、乙酸钠、苯扎氯铵和无菌水。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite significant progress in orthopaedic surgery, the prevalence of periprosthetic joint infections (PJIs) remains persistent, and future increases are expected due to the increasing number of joint arthroplasties. PJIs are intricately connected to biofilm-producing bacteria, which encase infected prostheses, impairing the effectiveness of antibiotics and the immune system. Acute PJIs with immature biofilms are traditionally managed with debridement, antibiotics, and implant retention (DAIR). However, to date, there has not been a conclusive direct clinical comparison (in vivo) demonstrating the superiority of one irrigation solution over others. Recently, there has been a growing interest in irrigation solutions with antibiofilm properties demonstrated in in vitro studies, exemplified by the preformulated Bactisure® irrigation solution, which contains ethanol, acetic acid, sodium acetate, benzalkonium chloride, and sterile water. The main objective of this study was to evaluate the effectiveness (infection cure rate) of preformulated Bactisure® irrigation solution in vivo compared with saline solution in a control group of patients with acute knee and/or hip periprosthetic infections treated with DAIR. METHODS: Prospective single-centre randomized controlled trial involving patients with acute haematogenous PJI who received standard DAIR surgery from December 2022 to December 2024. The type of irrigation solution used during surgery will include two groups allocated at a 1:1 ratio: a control group (n = 25) with saline solution and an experimental group (n = 25) receiving the Bactisure® preformulated solution. The sample size was calculated based on an expected reduction in reinfection rates from 45% in the control group to 10% in the experimental group. Data on baseline patient characteristics, clinical and radiological information, and healthcare questionnaires will be recorded. All patients will be followed for minimum of 12 months. The infection cure rate at 1 year will be the primary outcome. DISCUSSION: This study is the first to compare the effectiveness of preformulated Bactisure® irrigation solution with that of saline solution in real clinical practice (in vivo) in patients with acute knee and/or hip periprosthetic infections treated with DAIR. Our main hypothesis is that, compared with saline solution, Bactisure® provides a better infection cure rate at 1 year post-DAIR. TRIAL REGISTRATION: International Standard Randomized Controlled Trial Number (ISRCTN): https://doi.org/10.1186/ISRCTN10873696 . Registered on December 19, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Oleo-Taltavull R, Vicente Gomà-Camps M, Joshi Jubert N, et al. Efficacy of the preformulated irrigation solution Bactisure® in acute periprosthetic joint infection debridement surgery: study protocol for a randomized controlled trial. Trials. 2024. PMID: 39550574. doi:10.1186/s13063-024-08637-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。